Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : KL003
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : $20.0 million
Deal Type : Series A Financing
Kanglin Secures $20M Series A to Advance Gene Therapy Developments
Details : The proceeds will be used to support the clinical development for the company’s lead asset, KL003, a lentiviral vector gene therapy, for the treatment of beta thalassemia and sickle cell disease.
Product Name : KL003
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
November 25, 2024
Lead Product(s) : KL003
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : $20.0 million
Deal Type : Series A Financing
Reset All
